Legend Biotech (LEGN) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Legend Biotech (LEGN) over the past year, gaining 792.8% versus a loss of 45.9%. Over five years, SLS leads with a +94.0% price change compared with -71.8% for LEGN. Legend Biotech is the larger company by market cap ($2.96 billion vs $2.78 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LEGN | SLS |
|---|---|---|
| Share price | $15.25 | $13.66 |
| Market cap | $2.96B | $2.78B |
| 1-day change | -5.28% | -8.08% |
| YTD return | -29.85% | +262.33% |
| 1-year return | -45.86% | +792.81% |
| 5-year return | -71.83% | +94.03% |
| Forward P/E | 28.89 | — |
| EPS (TTM) | $-0.02 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.03B | — |
| Revenue growth (YoY) | +64.04% | — |
| Net income (latest FY) | $-296.80M | $-26.86M |
| Gross margin | 61.41% | — |
| Operating margin | -13.27% | — |
| Net margin | -28.85% | — |
| 52-week high | $37.50 | $24.89 |
| 52-week low | $15.15 | $1.39 |
| Distance from 52-week high | -59.33% | -45.12% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +168.39% | +137.92% |
| Average volume | 2.26M | 9.64M |
| Shares outstanding | 193.97M | 203.86M |
| Employees | 3,300 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed LEGN by 838.7 percentage points over the past year.
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,300 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
LEGN vs SLS FAQ
Which is bigger, Legend Biotech or SELLAS Life Sciences Group?
Legend Biotech (LEGN) is larger, with a market capitalization of $2.96B compared with $2.78B for SELLAS Life Sciences Group (SLS).
Which stock has performed better over the past year, LEGN or SLS?
SLS returned +792.81% over the past 12 months, compared with -45.86% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are Legend Biotech and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.